BIOLASE Inc (NASDAQ:BIOL) Given Average Rating of “Buy” by Brokerages

BIOLASE Inc (NASDAQ:BIOL) has been assigned a consensus rating of “Buy” from the six analysts that are presently covering the company, reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $2.50.

Several equities research analysts have recently weighed in on BIOL shares. Zacks Investment Research upgraded shares of BIOLASE from a “sell” rating to a “hold” rating in a research note on Tuesday, January 7th. ValuEngine upgraded shares of BIOLASE from a “hold” rating to a “buy” rating in a research note on Thursday, October 17th.

NASDAQ BIOL traded up $0.06 during trading on Friday, reaching $0.75. The company’s stock had a trading volume of 3,600 shares, compared to its average volume of 149,103. The business’s fifty day moving average price is $0.55 and its 200-day moving average price is $0.95. BIOLASE has a twelve month low of $0.43 and a twelve month high of $2.87. The company has a debt-to-equity ratio of 3.51, a quick ratio of 0.84 and a current ratio of 1.66. The firm has a market cap of $18.29 million, a price-to-earnings ratio of -0.88 and a beta of 2.16.

BIOLASE (NASDAQ:BIOL) last announced its earnings results on Wednesday, November 6th. The medical technology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.13. BIOLASE had a negative net margin of 52.13% and a negative return on equity of 313.64%. The business had revenue of $8.65 million during the quarter. As a group, sell-side analysts forecast that BIOLASE will post -0.69 EPS for the current fiscal year.

In other BIOLASE news, major shareholder Larry N. Feinberg bought 17,391 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The stock was acquired at an average price of $57.50 per share, for a total transaction of $999,982.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.50% of the stock is currently owned by corporate insiders.

A hedge fund recently raised its stake in BIOLASE stock. BlackRock Inc. increased its position in shares of BIOLASE Inc (NASDAQ:BIOL) by 3.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 298,875 shares of the medical technology company’s stock after purchasing an additional 9,698 shares during the period. BlackRock Inc. owned approximately 1.40% of BIOLASE worth $440,000 as of its most recent SEC filing. 26.88% of the stock is owned by hedge funds and other institutional investors.


BIOLASE, Inc, a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening.

Read More: Why do companies engage in swaps?

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with's FREE daily email newsletter.